智通财经APP讯，长春高新(000661.SZ)公告，公司子公司——长春金赛药业有限责任公司(“金赛药业”)收到美国食品药品监督管理局(“FDA”)书面通知，金赛药业注射用GenSci143临床试验申请获得受理，适应症为：晚期实体瘤。
智通财经APP讯，长春高新(000661.SZ)公告，公司子公司——长春金赛药业有限责任公司(“金赛药业”)收到美国食品药品监督管理局(“FDA”)书面通知，金赛药业注射用GenSci143临床试验申请获得受理，适应症为：晚期实体瘤。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.